Literature DB >> 25867322

C-erbB-2 expression and prognosis of gastric cancer: a meta-analysis.

Z Q Wang1, B J Sun2.   

Abstract

The prognostic role of c-erbB-2 in gastric cancer is controversial. We conducted a meta-analysis to evaluate the relationship between c-erbB-2 expression and the prognosis of gastric cancer. We evaluated 20 published studies assessing the relationship between c-erbB-2 and gastric cancer prognosis. The Revman 5.0 software was used to perform literature retrieval, article selection, data collection, and statistical analysis. We utilized a fixed-effect model to pool hazard ratios and 95% confidence intervals from the studies. A total of 20 eligible studies including 4468 gastric cancer patients were analyzed. We were unable to demonstrate the prognostic value of c-erbB-2 for gastric cancer (hazard ratio = 1.01, 95% confidence interval = 0.87-1.16, P = 0.93). The present study indicated that c-erbB-2 expression is not a prognostic factor for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25867322     DOI: 10.4238/2015.March.13.5

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  3 in total

1.  Prognostic Biomarkers for Gastric Cancer: An Umbrella Review of the Evidence.

Authors:  Cen Zhou; Xi Zhong; Yongxi Song; Jinxin Shi; Zhonghua Wu; Zhexu Guo; Jie Sun; Zhenning Wang
Journal:  Front Oncol       Date:  2019-11-29       Impact factor: 6.244

2.  Elevated HOXA1 expression correlates with accelerated tumor cell proliferation and poor prognosis in gastric cancer partly via cyclin D1.

Authors:  Chenwei Yuan; Xingwu Zhu; Yang Han; Chenlong Song; Chenchen Liu; Su Lu; Meng Zhang; Fudong Yu; Zhihai Peng; Chongzhi Zhou
Journal:  J Exp Clin Cancer Res       Date:  2016-01-21

Review 3.  Prognostic Value and Clinicopathological Significance of p-stat3 Among Gastric Carcinoma Patients: A Systematic Review and Meta-Analysis.

Authors:  Kun Ji; Liyan Zhang; Mingxuan Zhang; Qi Chu; Xin Li; Wei Wang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.